Business Wire

Largest Observational Study to Date of the St. Jude Medical AMPLATZER Amulet Left Atrial Appendage Occluder Demonstrates High Implant Success and Strong Safety Profile

Del

St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today presented favorable results from the largest observational study to date of the company’s AMPLATZER™ Amulet™ left atrial appendage (LAA) occluder. The data were presented in a Late Breaking Clinical Trial session at the Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington, D.C.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161102005979/en/

The St. Jude Medical(TM) AMPLATZER(TM) Amulet(TM) device is used to completely seal off the left atr ...

The St. Jude Medical(TM) AMPLATZER(TM) Amulet(TM) device is used to completely seal off the left atrial appendage (LAA) in patients diagnosed with non-valvular atrial fibrillation (AF). Sealing off the LAA in patients with AF may prevent the risk of blood clot formation and release, potentially reducing that risk. (Photo: St. Jude Medical)

The prospective, multicenter, international AMPLATZER Amulet Observational Study of LAA occlusion (closure) enrolled 1,073 patients at 64 centers across 18 countries. Initial results from the study showed a 98.8 percent implant success rate adding to the clinical evidence that the AMPLATZER Amulet LAA Occluder is a safe alternative for prevention of stroke in patients with non-valvular atrial fibrillation (AF).

The AMPLATZER Amulet LAA Occluder is used to close the LAA (an appendage of the left atrium) in patients diagnosed with non-valvular AF. Atrial fibrillation occurs when the upper chambers of the heart (atria) contract rapidly and irregularly, which can disrupt efficient pumping of the blood out of the heart. Blood that pools in the atria can clot and, if the clot moves to an artery in the brain, stroke may occur. Studies have shown that AF can dramatically increase the risk of stroke for patients and for many patients, medication has historically been the option physicians turn to most often.

“Patients with atrial fibrillation at risk of stroke are usually prescribed anticoagulant medication, but this treatment comes with some limitations. Patients might not tolerate the medication, plus there’s a risk for major bleeding,” said Dr. David Hildick-Smith from Sussex Cardiac Centre at Brighton and Sussex University Hospitals Brighton, United Kingdom and principal investigator of the AMPLATZER Amulet Observational Study. “By closing the LAA with the AMPLATZER Amulet device, physicians can seal off the LAA, with the objective of reducing the risk of stroke and eliminating the need for oral anticoagulants.”

Other key findings of the Amulet Observational study include:

  • Closure rate was 99 percent at one to three month follow-up visit (n=364). Closure was defined as absence of flow or flow of < 3 mm jet into the LAA. All echocardiography results were adjudicated by an independent core lab.
  • Acute device/procedure related major adverse events within seven days post procedure occurred in 2.7 percent (29) of 1,073 patients.

“Initial data from this large-scale observational study continue to affirm the AMPLATZER Amulet LAA Occluder as an important treatment option to reduce the risk of stroke in patients with non-valvular AF,” said Dr. Srijoy Mahapatra, medical director and vice president of medical affairs at St. Jude Medical. “The AMPLATZER Amulet Occluder has favorable closure rates when compared to other device reports in a similar patient group.”

The AMPLATZER Amulet Left Atrial Appendage Occluder is CE Mark approved, but remains an investigational device in the United States. In September, St. Jude Medical announced the start of the AMPLATZER™ Amulet™ LAA Occluder IDE trial, evaluating the safety and effectiveness of the company’s AMPLATZER Amulet occluder device. The trial will enroll patients at up to 100 sites in the United States and an additional 50 sites internationally.

The shape and size of an LAA can vary greatly. The AMPLATZER Amulet LAA Occluder has a conformable disc and lobe designed for complete occlusion of the LAA and offers the broadest size range available. The device offers physicians options to help meet the anatomical demands of patients in need of LAA closure.

About Atrial Fibrillation and Stroke

During AF, chaotic electrical signals in the heart’s upper chambers (atria) beat erratically and out of sync with the two lower chambers, resulting in poor blood flow. The LAA is a tube-shaped appendage connected to the left atrium of the heart that can potentially hold static blood during an episode of AF, increasing the likelihood of clot formation. Research shows that in AF patients, approximately 90 percent of all cardiac blood clots form in the LAA. If a clot forms in the LAA and is then released into the heart, it may enter blood circulation, travel to the brain, block a vessel and cause an ischemic stroke. The current standard of care to treat ischemic stroke in AF patients is blood-thinning medications, which comes with major, sometimes fatal, bleeding risks.

According to the World Health Organization (WHO), an estimated 15 million strokes occur worldwide each year. In 2010, stroke cost the United States an estimated $53.9 billion in health care services, medications and missed days of work.

About St. Jude Medical

St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management, and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the company, including potential clinical successes, reimbursement strategies, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the company’s control and the risk factors and other cautionary statements described in the company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended July 2, 2016. The company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

Contact information

St. Jude Medical, Inc.
Investor Relations:
J.C. Weigelt, 651-756-4347
jweigelt@sjm.com
or
Media Relations:
Gina O'Connell, 651-756-3380
goconnell02@sjm.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Sigma Systems CTO Catherine Michel to Speak at Women in Communications Event24.10.2017 09:00Pressemelding

Sigma Systems, the global leader in catalog-driven software, has confirmed today that its Chief Technology Officer, Catherine Michel, will be speaking at Light Reading’s Women in Comms luncheon to be held November 1st in London. The event will take place during Light Reading’s OSS in the Era of SDN and NFV conference. Speakers include the editors of Light Reading and analysts of Heavy Reading, alongside industry guest speakers including Sigma’s Catherine Michel. This event brings together leading women in communications and their male allies to discuss everything related to the state of the industry today, including why diversity in the workplace matters, and why companies should care about the disparity in representation and pay of female employees. Earlier this year, Catherine was named to the top 50 Women to Watch 2017 and the Power 100 by Global Telecoms Business - the o

GSMA Mobile IoT Initiative Helping Operators Target European Connected Energy Market Worth USD$26 Billion24.10.2017 08:00Pressemelding

The GSMA today announced that mobile operators deploying new Mobile IoT networks will be able to benefit from the European connected energy market estimated to be worth USD$26 billion by 20261. Data shared by analyst house Machina Research highlights the huge growth opportunity in the emerging connected energy market that could connect approximately 158 million new smart meters on LPWA networks across Europe. The total number of connections in Europe could be further increased if the 60 million cellular connections are also included with LPWA. “The Internet of Things is fundamentally disrupting the smart utility market by providing ubiquitous connectivity and real-time, actionable data. Mobile IoT networks will take this further by offering energy providers a cost-effective solution to connect millions of smart meters,” said Alex Sinclair, Chief Technology Officer, GSMA. “There is a

RevolutionAir: Philips Launches a Brand-New Wireless SpeechMike Premium Air24.10.2017 07:02Pressemelding

Speech Processing Solutions, the world’s number one in professional dictation, has just released its latest innovation, the wireless SpeechMike Premium Air dictation microphone. For the first time in history, the new device offers not only outstanding audio recording quality, enabling exceptional speech recognition results, best in class quality and ergonomics, but also a wireless dictation microphone, based on 100% lossless speech technology. The dictation microphone allows users to quickly turn their voice into text, saving them time and making them more effective at their core profession. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005093/en/ Philips SpeechMike Premium Air (Photo: Business Wire) Lossless speech technology The high-quality device deliver

Philip Morris International Recognized for Environmental Leadership on CDP’s A List for Climate and Water24.10.2017 07:00Pressemelding

Philip Morris International Inc. (“PMI”) (NYSE/Euronext Paris: PM) today was again recognized as a global leader for environmental action in the annual CDP rankings. For the fourth year in a row, PMI is on the CDP Climate A List for taking comprehensive action on climate change and for its transparent disclosure process. In addition, PMI achieved A List status for CDP Water, recognizing the company’s water stewardship initiatives. PMI is one of only 25 companies that scored an A for both climate and water, placing the company in the top 1% of corporations known as the “A Listers” for both schemes. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171024005711/en/ CDP, formerly known as the Carbon Disclosure Project, is the leading international not-for-profit organization independently assessing the environmental efforts of t

QVC Makes the Leap into Ultra HD in Germany with SES Video24.10.2017 06:50Pressemelding

QVC will bring an enhanced TV experience to its viewers with the launch of its Ultra HD channel in Germany, the seventh channel in ultra-high definition in the country, via SES’s prime orbital slot 19.2 degrees East. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171023005870/en/ QVC Makes the Leap into Ultra HD in Germany with SES Video (Photo: Business Wire) Under the ten-year agreement announced by SES, QVC will utilize additional capacity for its upgrade to Ultra HD and rely on SES’s wholly-owned subsidiary MX1 for encoding in HEVC format and uplink services. QVC is also renewing capacity for distribution of the channel in Standard and High Definition. “As we carry the largest line-up of HD and UHD channels worldwide, it is part of our DNA to help our customers bring the best pos

Visa Launches Foundation With Inaugural Grant to Women’s World Banking24.10.2017 06:30Pressemelding

Visa (NYSE:V) today marked the launch of the newly-incorporated Visa Foundation, which has been established as part of Visa’s larger social impact strategy that will prioritize the growth of micro and small enterprises around the world, enabling individuals, businesses, and economies to thrive. To mark its inception, the Visa Foundation is making its first financial commitment of up to $20 million to Women’s World Banking. At the heart of the Visa Foundation is the belief that micro and small enterprises are the backbone of the global economy. In fact, small and medium enterprises account for more than 90 percent of enterprises worldwide, and contribute 50-60 percent of global employment.1 However, these segments struggle to access the financial tools, capital and training programs required to enable them to fully thrive. The Visa Foundation’s core mission is to support efforts to rect

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom